FINAL REJECTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-18 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement.
The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The new claim limitation of “the at least one first microneedle and the at least one second microneedle overlap in the direction of displacement relative to one another in … the disengaged state” is not disclosed in the specification or drawings.
Response to Arguments
In Applicant’s remarks filed 09/03/2026 attention is drawn to Figs. 1, 2, 4, 8c and 10 as showing the overlap of the first and second microneedles in the “X” direction. However, these figures do not show this orientation. Fig. 1 is disclosed as showing the microneedle based delivery system in the disengaged state. However, the microneedles themselves are barely visible and one skilled in the art would not be able to determine if the first and second microneedles are overlapping in the “X” direction. Fig. 2 is a closer view of the delivery system of Fig. 1. However, the first and second needles are not clearly overlapping in a “X” direction; rather, the needles seem to be laterally displaced with no overlapping. Fig. 4 shows a cut away perspective of the delivery system. Similar to Fig. 2, the first and second needles are not clearly overlapping in a “X” direction; rather, the needles seem to be laterally displaced with no overlapping. Fig. 8c shows a cross section of the delivery system in the disengaged state. However, the first and second needles are not clearly overlapping in a “X” direction; rather, the needles seem to be laterally displaced with no overlapping. Fig. 10 shows a front elevation of the delivery system of Fig. 9. Fig. 9 clearly shows that the first and second microneedles are not overlapping. The elevation of Fig. 10 does not clearly show that the first and second microneedles are overlapping in the “X” direction.
Furthermore, the specification (para. [0073] in US Pub. No. 2024/0207589) states, “[r]eferring to FIG. 4 it can be seen that when the system 10 is in the disengaged state the upper ends of the delivery conduits 26, 28 are spaced from one another in the “X” direction” (emphasis added); therefore, the first and second microneedles are not overlapping in the disengaged state in the “X” direction.
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
The previous rejection of claims 7-9 and 11-13 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, has been withdrawn in light of the amendment to the claims filed 09/03/2026.
Claim Rejections - 35 USC § 102
The previous rejection of claim(s) 1-7, 10-11 and 16-18 under 35 U.S.C. 102(a)(1) as being anticipated by WO2012/006677 to Kendall et al. (“Kendall”) has been withdrawn in light of the amendment to the claims filed 09/03/2026.
Kendall does not disclose or render obvious the at least one first microneedle and the at least one second microneedle overlap in the direction of displacement relative to one another in both the disengaged state and the engaged state.
The previous rejection of claim(s) 1 and 6-10 under 35 U.S.C. 102(a)(1) as being anticipated by US2009/0270906 to Hossainy (“Hossainy”) has been withdrawn in light of the amendment to the claims filed 09/03/2026.
Hossainy does not disclose or render obvious the at least one first microneedle and the at least one second microneedle overlap in the direction of displacement relative to one another in both the disengaged state and the engaged state.
Claim Rejections - 35 USC § 103
The previous rejection of claim(s) 14-15 under 35 U.S.C. 103 as being unpatentable over Kendall in view of US2019/0134370 to Sumida (“Sumida”) has been withdrawn in light of the amendment to the claims filed 09/03/2026. See above.
Response to Arguments
Applicant’s arguments, filed 09/03/2026, with respect to the claim amendment to claim 1 have been fully considered and are persuasive. The previous rejections been withdrawn.
Pertinent Prior Art
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. WO2013/090844; KR20070091115 and WO03/074102.
Conclusion
THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERINE SERKE WILLIAMS whose telephone number is (571)272-4970. The examiner can normally be reached Monday through Friday core hours 8am-4pm ET.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Eileen Lillis can be reached at 571-272-6928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/CATHERINE S WILLIAMS/Primary Examiner, Art Unit 3993